nodes	percent_of_prediction	percent_of_DWPC	metapath
Etomidate—CYP19A1—ovarian follicle—hematologic cancer	0.0455	0.22	CbGeAlD
Etomidate—CYP19A1—Betamethasone—hematologic cancer	0.0274	0.632	CbGbCtD
Etomidate—SLC2A1—hematopoietic system—hematologic cancer	0.0174	0.084	CbGeAlD
Etomidate—CYP19A1—Dexamethasone—hematologic cancer	0.016	0.368	CbGbCtD
Etomidate—CYP11B2—hematopoietic system—hematologic cancer	0.0149	0.0719	CbGeAlD
Etomidate—CYP11B1—hematopoietic system—hematologic cancer	0.0149	0.0719	CbGeAlD
Etomidate—SLC2A1—gonad—hematologic cancer	0.0132	0.0639	CbGeAlD
Etomidate—SLC2A1—blood—hematologic cancer	0.0115	0.0557	CbGeAlD
Etomidate—SLC2A1—bone marrow—hematologic cancer	0.0111	0.0539	CbGeAlD
Etomidate—SLC2A1—lung—hematologic cancer	0.0101	0.0488	CbGeAlD
Etomidate—CYP11B1—blood—hematologic cancer	0.00985	0.0477	CbGeAlD
Etomidate—CYP11B2—blood—hematologic cancer	0.00985	0.0477	CbGeAlD
Etomidate—SLC2A1—testis—hematologic cancer	0.00952	0.046	CbGeAlD
Etomidate—SLC2A1—lymph node—hematologic cancer	0.0069	0.0334	CbGeAlD
Etomidate—CYP11B2—lymph node—hematologic cancer	0.00591	0.0286	CbGeAlD
Etomidate—CYP19A1—hematopoietic system—hematologic cancer	0.00549	0.0266	CbGeAlD
Etomidate—CYP19A1—gonad—hematologic cancer	0.00418	0.0202	CbGeAlD
Etomidate—GABRB2—lung—hematologic cancer	0.00393	0.019	CbGeAlD
Etomidate—GABRB2—testis—hematologic cancer	0.00371	0.018	CbGeAlD
Etomidate—CYP19A1—blood—hematologic cancer	0.00364	0.0176	CbGeAlD
Etomidate—Pseudoephedrine—IL2—hematologic cancer	0.00319	0.595	CrCbGaD
Etomidate—CYP19A1—testis—hematologic cancer	0.00301	0.0146	CbGeAlD
Etomidate—CYP19A1—lymph node—hematologic cancer	0.00218	0.0106	CbGeAlD
Etomidate—Hiccups—Triamcinolone—hematologic cancer	0.00149	0.00422	CcSEcCtD
Etomidate—Arrhythmia—Fludarabine—hematologic cancer	0.00149	0.00422	CcSEcCtD
Etomidate—Convulsion—Idarubicin—hematologic cancer	0.00147	0.00416	CcSEcCtD
Etomidate—Hypotension—Nelarabine—hematologic cancer	0.00144	0.00408	CcSEcCtD
Etomidate—Hypertension—Teniposide—hematologic cancer	0.00142	0.00404	CcSEcCtD
Etomidate—Tachycardia—Clofarabine—hematologic cancer	0.00141	0.00399	CcSEcCtD
Etomidate—Tachycardia—Daunorubicin—hematologic cancer	0.00141	0.00399	CcSEcCtD
Etomidate—Hypotension—Methoxsalen—hematologic cancer	0.0014	0.00398	CcSEcCtD
Etomidate—Tachycardia—Anagrelide—hematologic cancer	0.0014	0.00397	CcSEcCtD
Etomidate—Tachycardia—Pentostatin—hematologic cancer	0.0014	0.00397	CcSEcCtD
Etomidate—Arrhythmia—Nilotinib—hematologic cancer	0.00138	0.00391	CcSEcCtD
Etomidate—Arrhythmia—Imatinib—hematologic cancer	0.00137	0.00388	CcSEcCtD
Etomidate—Bradycardia—Lenalidomide—hematologic cancer	0.00136	0.00386	CcSEcCtD
Etomidate—Vomiting—Vorinostat—hematologic cancer	0.00135	0.00383	CcSEcCtD
Etomidate—Hiccups—Betamethasone—hematologic cancer	0.00135	0.00383	CcSEcCtD
Etomidate—Hiccups—Dexamethasone—hematologic cancer	0.00135	0.00383	CcSEcCtD
Etomidate—Hypotension—Clofarabine—hematologic cancer	0.00135	0.00382	CcSEcCtD
Etomidate—Arrhythmia—Cladribine—hematologic cancer	0.00135	0.00382	CcSEcCtD
Etomidate—Hypotension—Pentostatin—hematologic cancer	0.00134	0.0038	CcSEcCtD
Etomidate—Hypotension—Anagrelide—hematologic cancer	0.00134	0.0038	CcSEcCtD
Etomidate—Hyperventilation—Epirubicin—hematologic cancer	0.00134	0.00379	CcSEcCtD
Etomidate—Convulsion—Busulfan—hematologic cancer	0.00132	0.00375	CcSEcCtD
Etomidate—Hypertension—Busulfan—hematologic cancer	0.00132	0.00374	CcSEcCtD
Etomidate—Pain—Nelarabine—hematologic cancer	0.00132	0.00373	CcSEcCtD
Etomidate—Tachycardia—Teniposide—hematologic cancer	0.00131	0.00372	CcSEcCtD
Etomidate—Convulsion—Procarbazine—hematologic cancer	0.00128	0.00364	CcSEcCtD
Etomidate—Hypertension—Procarbazine—hematologic cancer	0.00128	0.00363	CcSEcCtD
Etomidate—Convulsion—Dasatinib—hematologic cancer	0.00126	0.00357	CcSEcCtD
Etomidate—Hypotension—Teniposide—hematologic cancer	0.00126	0.00356	CcSEcCtD
Etomidate—Convulsion—Fludarabine—hematologic cancer	0.00126	0.00356	CcSEcCtD
Etomidate—Hypertension—Dasatinib—hematologic cancer	0.00125	0.00356	CcSEcCtD
Etomidate—Hypertension—Bexarotene—hematologic cancer	0.00125	0.00356	CcSEcCtD
Etomidate—Bradycardia—Bortezomib—hematologic cancer	0.00125	0.00355	CcSEcCtD
Etomidate—Hyperventilation—Doxorubicin—hematologic cancer	0.00124	0.00351	CcSEcCtD
Etomidate—Pain—Clofarabine—hematologic cancer	0.00123	0.00349	CcSEcCtD
Etomidate—Pain—Daunorubicin—hematologic cancer	0.00123	0.00349	CcSEcCtD
Etomidate—Arrhythmia—Melphalan—hematologic cancer	0.00123	0.00348	CcSEcCtD
Etomidate—Pain—Anagrelide—hematologic cancer	0.00123	0.00348	CcSEcCtD
Etomidate—Pain—Pentostatin—hematologic cancer	0.00123	0.00348	CcSEcCtD
Etomidate—Tachycardia—Busulfan—hematologic cancer	0.00122	0.00345	CcSEcCtD
Etomidate—Vomiting—Lomustine—hematologic cancer	0.00121	0.00343	CcSEcCtD
Etomidate—Arrhythmia—Lenalidomide—hematologic cancer	0.00119	0.00339	CcSEcCtD
Etomidate—Convulsion—Chlorambucil—hematologic cancer	0.00119	0.00337	CcSEcCtD
Etomidate—Tachycardia—Procarbazine—hematologic cancer	0.00118	0.00335	CcSEcCtD
Etomidate—Hiccups—Prednisone—hematologic cancer	0.00118	0.00333	CcSEcCtD
Etomidate—Hypotension—Busulfan—hematologic cancer	0.00116	0.0033	CcSEcCtD
Etomidate—Vomiting—Mechlorethamine—hematologic cancer	0.00116	0.00329	CcSEcCtD
Etomidate—Apnoea—Methotrexate—hematologic cancer	0.00116	0.00329	CcSEcCtD
Etomidate—Hypertension—Nilotinib—hematologic cancer	0.00116	0.00329	CcSEcCtD
Etomidate—Tachycardia—Dasatinib—hematologic cancer	0.00116	0.00328	CcSEcCtD
Etomidate—Tachycardia—Bexarotene—hematologic cancer	0.00116	0.00328	CcSEcCtD
Etomidate—Convulsion—Imatinib—hematologic cancer	0.00116	0.00328	CcSEcCtD
Etomidate—Hypertension—Imatinib—hematologic cancer	0.00115	0.00327	CcSEcCtD
Etomidate—Hypotension—Procarbazine—hematologic cancer	0.00113	0.0032	CcSEcCtD
Etomidate—Bradycardia—Thalidomide—hematologic cancer	0.00113	0.0032	CcSEcCtD
Etomidate—Hypotension—Dasatinib—hematologic cancer	0.00111	0.00314	CcSEcCtD
Etomidate—Arrhythmia—Bortezomib—hematologic cancer	0.0011	0.00311	CcSEcCtD
Etomidate—Convulsion—Vinblastine—hematologic cancer	0.00109	0.00309	CcSEcCtD
Etomidate—Hypertension—Vinblastine—hematologic cancer	0.00109	0.00308	CcSEcCtD
Etomidate—Pseudoephedrine—TNF—hematologic cancer	0.00108	0.201	CrCbGaD
Etomidate—Arrhythmia—Vinorelbine—hematologic cancer	0.00107	0.00304	CcSEcCtD
Etomidate—Tachycardia—Nilotinib—hematologic cancer	0.00107	0.00303	CcSEcCtD
Etomidate—Pain—Busulfan—hematologic cancer	0.00107	0.00302	CcSEcCtD
Etomidate—Tachycardia—Imatinib—hematologic cancer	0.00106	0.00301	CcSEcCtD
Etomidate—Bradycardia—Ifosfamide—hematologic cancer	0.00106	0.00301	CcSEcCtD
Etomidate—Tachycardia—Cladribine—hematologic cancer	0.00104	0.00296	CcSEcCtD
Etomidate—Convulsion—Melphalan—hematologic cancer	0.00104	0.00294	CcSEcCtD
Etomidate—Pain—Procarbazine—hematologic cancer	0.00103	0.00293	CcSEcCtD
Etomidate—Arrhythmia—Thiotepa—hematologic cancer	0.00102	0.0029	CcSEcCtD
Etomidate—Hypotension—Nilotinib—hematologic cancer	0.00102	0.0029	CcSEcCtD
Etomidate—Hypotension—Imatinib—hematologic cancer	0.00102	0.00289	CcSEcCtD
Etomidate—Pain—Dasatinib—hematologic cancer	0.00101	0.00288	CcSEcCtD
Etomidate—Pain—Bexarotene—hematologic cancer	0.00101	0.00288	CcSEcCtD
Etomidate—Pain—Fludarabine—hematologic cancer	0.00101	0.00287	CcSEcCtD
Etomidate—Bradycardia—Irinotecan—hematologic cancer	0.00101	0.00286	CcSEcCtD
Etomidate—Bradycardia—Mitoxantrone—hematologic cancer	0.00101	0.00286	CcSEcCtD
Etomidate—Hypertension—Lenalidomide—hematologic cancer	0.001	0.00285	CcSEcCtD
Etomidate—Respiratory failure—Methotrexate—hematologic cancer	0.001	0.00284	CcSEcCtD
Etomidate—Hypotension—Cladribine—hematologic cancer	0.001	0.00284	CcSEcCtD
Etomidate—Convulsion—Hydroxyurea—hematologic cancer	0.000994	0.00282	CcSEcCtD
Etomidate—Arrhythmia—Thalidomide—hematologic cancer	0.000991	0.00281	CcSEcCtD
Etomidate—Vomiting—Nelarabine—hematologic cancer	0.000978	0.00277	CcSEcCtD
Etomidate—Pain—Chlorambucil—hematologic cancer	0.000958	0.00272	CcSEcCtD
Etomidate—Tachycardia—Melphalan—hematologic cancer	0.000953	0.0027	CcSEcCtD
Etomidate—Arrhythmia—Carmustine—hematologic cancer	0.000951	0.0027	CcSEcCtD
Etomidate—Arrhythmia—Alitretinoin—hematologic cancer	0.000942	0.00267	CcSEcCtD
Etomidate—Pain—Nilotinib—hematologic cancer	0.000937	0.00266	CcSEcCtD
Etomidate—Arrhythmia—Ifosfamide—hematologic cancer	0.000931	0.00264	CcSEcCtD
Etomidate—Pain—Imatinib—hematologic cancer	0.000931	0.00264	CcSEcCtD
Etomidate—Vomiting—Mercaptopurine—hematologic cancer	0.000929	0.00263	CcSEcCtD
Etomidate—Convulsion—Bortezomib—hematologic cancer	0.000927	0.00263	CcSEcCtD
Etomidate—Tachycardia—Lenalidomide—hematologic cancer	0.000926	0.00263	CcSEcCtD
Etomidate—Hypertension—Bortezomib—hematologic cancer	0.000924	0.00262	CcSEcCtD
Etomidate—Hiccups—Epirubicin—hematologic cancer	0.000919	0.00261	CcSEcCtD
Etomidate—Vomiting—Daunorubicin—hematologic cancer	0.000916	0.0026	CcSEcCtD
Etomidate—Vomiting—Clofarabine—hematologic cancer	0.000916	0.0026	CcSEcCtD
Etomidate—Bradycardia—Cisplatin—hematologic cancer	0.000915	0.0026	CcSEcCtD
Etomidate—Pain—Cladribine—hematologic cancer	0.000915	0.0026	CcSEcCtD
Etomidate—Hypotension—Melphalan—hematologic cancer	0.000912	0.00259	CcSEcCtD
Etomidate—Vomiting—Pentostatin—hematologic cancer	0.000912	0.00259	CcSEcCtD
Etomidate—Vomiting—Anagrelide—hematologic cancer	0.000912	0.00259	CcSEcCtD
Etomidate—Hypertension—Vinorelbine—hematologic cancer	0.000902	0.00256	CcSEcCtD
Etomidate—Hypotension—Lenalidomide—hematologic cancer	0.000887	0.00252	CcSEcCtD
Etomidate—Arrhythmia—Mitoxantrone—hematologic cancer	0.000884	0.00251	CcSEcCtD
Etomidate—Arrhythmia—Irinotecan—hematologic cancer	0.000884	0.00251	CcSEcCtD
Etomidate—Vomiting—Idarubicin—hematologic cancer	0.000879	0.00249	CcSEcCtD
Etomidate—Pain—Vinblastine—hematologic cancer	0.000878	0.00249	CcSEcCtD
Etomidate—Convulsion—Thiotepa—hematologic cancer	0.000865	0.00245	CcSEcCtD
Etomidate—Hypertension—Thiotepa—hematologic cancer	0.000862	0.00244	CcSEcCtD
Etomidate—Arrhythmia—Gemcitabine—hematologic cancer	0.000862	0.00244	CcSEcCtD
Etomidate—Vomiting—Teniposide—hematologic cancer	0.000855	0.00243	CcSEcCtD
Etomidate—Tachycardia—Bortezomib—hematologic cancer	0.000853	0.00242	CcSEcCtD
Etomidate—Hiccups—Doxorubicin—hematologic cancer	0.000851	0.00241	CcSEcCtD
Etomidate—Convulsion—Thalidomide—hematologic cancer	0.000836	0.00237	CcSEcCtD
Etomidate—Pain—Melphalan—hematologic cancer	0.000835	0.00237	CcSEcCtD
Etomidate—Hypertension—Thalidomide—hematologic cancer	0.000833	0.00236	CcSEcCtD
Etomidate—Tachycardia—Vinorelbine—hematologic cancer	0.000832	0.00236	CcSEcCtD
Etomidate—Bradycardia—Prednisolone—hematologic cancer	0.000827	0.00235	CcSEcCtD
Etomidate—Hypotension—Bortezomib—hematologic cancer	0.000816	0.00231	CcSEcCtD
Etomidate—Pain—Lenalidomide—hematologic cancer	0.000812	0.0023	CcSEcCtD
Etomidate—Hypotension—Bleomycin—hematologic cancer	0.00081	0.0023	CcSEcCtD
Etomidate—Convulsion—Carmustine—hematologic cancer	0.000803	0.00228	CcSEcCtD
Etomidate—Arrhythmia—Cisplatin—hematologic cancer	0.000803	0.00228	CcSEcCtD
Etomidate—Hypertension—Carmustine—hematologic cancer	0.0008	0.00227	CcSEcCtD
Etomidate—Pain—Hydroxyurea—hematologic cancer	0.0008	0.00227	CcSEcCtD
Etomidate—Hypotension—Vinorelbine—hematologic cancer	0.000797	0.00226	CcSEcCtD
Etomidate—Convulsion—Alitretinoin—hematologic cancer	0.000796	0.00226	CcSEcCtD
Etomidate—Tachycardia—Thiotepa—hematologic cancer	0.000795	0.00225	CcSEcCtD
Etomidate—Hypertension—Alitretinoin—hematologic cancer	0.000793	0.00225	CcSEcCtD
Etomidate—Vomiting—Busulfan—hematologic cancer	0.000793	0.00225	CcSEcCtD
Etomidate—Convulsion—Ifosfamide—hematologic cancer	0.000786	0.00223	CcSEcCtD
Etomidate—Hypertension—Ifosfamide—hematologic cancer	0.000784	0.00222	CcSEcCtD
Etomidate—Vomiting—Procarbazine—hematologic cancer	0.000769	0.00218	CcSEcCtD
Etomidate—Tachycardia—Thalidomide—hematologic cancer	0.000769	0.00218	CcSEcCtD
Etomidate—Convulsion—Vincristine—hematologic cancer	0.000767	0.00217	CcSEcCtD
Etomidate—Hypertension—Vincristine—hematologic cancer	0.000764	0.00217	CcSEcCtD
Etomidate—Bradycardia—Triamcinolone—hematologic cancer	0.00076	0.00216	CcSEcCtD
Etomidate—Vomiting—Bexarotene—hematologic cancer	0.000754	0.00214	CcSEcCtD
Etomidate—Vomiting—Dasatinib—hematologic cancer	0.000754	0.00214	CcSEcCtD
Etomidate—Vomiting—Fludarabine—hematologic cancer	0.000752	0.00213	CcSEcCtD
Etomidate—Pain—Bortezomib—hematologic cancer	0.000747	0.00212	CcSEcCtD
Etomidate—Convulsion—Mitoxantrone—hematologic cancer	0.000747	0.00212	CcSEcCtD
Etomidate—Hypertension—Irinotecan—hematologic cancer	0.000744	0.00211	CcSEcCtD
Etomidate—Hypertension—Mitoxantrone—hematologic cancer	0.000744	0.00211	CcSEcCtD
Etomidate—Pain—Bleomycin—hematologic cancer	0.000741	0.0021	CcSEcCtD
Etomidate—Tachycardia—Carmustine—hematologic cancer	0.000738	0.00209	CcSEcCtD
Etomidate—Hypotension—Thalidomide—hematologic cancer	0.000736	0.00209	CcSEcCtD
Etomidate—Tachycardia—Alitretinoin—hematologic cancer	0.000732	0.00207	CcSEcCtD
Etomidate—Pain—Vinorelbine—hematologic cancer	0.000729	0.00207	CcSEcCtD
Etomidate—Arrhythmia—Prednisolone—hematologic cancer	0.000726	0.00206	CcSEcCtD
Etomidate—Hypertension—Gemcitabine—hematologic cancer	0.000725	0.00206	CcSEcCtD
Etomidate—Vomiting—Chlorambucil—hematologic cancer	0.000712	0.00202	CcSEcCtD
Etomidate—Hypotension—Carmustine—hematologic cancer	0.000707	0.00201	CcSEcCtD
Etomidate—Hypotension—Alitretinoin—hematologic cancer	0.0007	0.00199	CcSEcCtD
Etomidate—Pain—Thiotepa—hematologic cancer	0.000697	0.00198	CcSEcCtD
Etomidate—Vomiting—Nilotinib—hematologic cancer	0.000696	0.00198	CcSEcCtD
Etomidate—Vomiting—Imatinib—hematologic cancer	0.000692	0.00196	CcSEcCtD
Etomidate—Hypotension—Ifosfamide—hematologic cancer	0.000692	0.00196	CcSEcCtD
Etomidate—Bradycardia—Dexamethasone—hematologic cancer	0.00069	0.00196	CcSEcCtD
Etomidate—Bradycardia—Betamethasone—hematologic cancer	0.00069	0.00196	CcSEcCtD
Etomidate—Tachycardia—Mitoxantrone—hematologic cancer	0.000686	0.00195	CcSEcCtD
Etomidate—Vomiting—Cladribine—hematologic cancer	0.00068	0.00193	CcSEcCtD
Etomidate—Convulsion—Cisplatin—hematologic cancer	0.000678	0.00192	CcSEcCtD
Etomidate—Hypotension—Vincristine—hematologic cancer	0.000675	0.00191	CcSEcCtD
Etomidate—Pain—Thalidomide—hematologic cancer	0.000674	0.00191	CcSEcCtD
Etomidate—Arrhythmia—Triamcinolone—hematologic cancer	0.000667	0.00189	CcSEcCtD
Etomidate—Hypotension—Mitoxantrone—hematologic cancer	0.000657	0.00186	CcSEcCtD
Etomidate—Hypotension—Irinotecan—hematologic cancer	0.000657	0.00186	CcSEcCtD
Etomidate—Vomiting—Vinblastine—hematologic cancer	0.000653	0.00185	CcSEcCtD
Etomidate—Pain—Carmustine—hematologic cancer	0.000647	0.00183	CcSEcCtD
Etomidate—Pain—Alitretinoin—hematologic cancer	0.000641	0.00182	CcSEcCtD
Etomidate—Hypotension—Gemcitabine—hematologic cancer	0.00064	0.00182	CcSEcCtD
Etomidate—Pain—Ifosfamide—hematologic cancer	0.000633	0.0018	CcSEcCtD
Etomidate—Fenoprofen—ALB—hematologic cancer	0.000625	0.117	CrCbGaD
Etomidate—Tachycardia—Cisplatin—hematologic cancer	0.000623	0.00177	CcSEcCtD
Etomidate—Convulsion—Etoposide—hematologic cancer	0.000621	0.00176	CcSEcCtD
Etomidate—Vomiting—Melphalan—hematologic cancer	0.000621	0.00176	CcSEcCtD
Etomidate—Hypertension—Etoposide—hematologic cancer	0.000619	0.00176	CcSEcCtD
Etomidate—Pain—Vincristine—hematologic cancer	0.000618	0.00175	CcSEcCtD
Etomidate—Convulsion—Prednisolone—hematologic cancer	0.000613	0.00174	CcSEcCtD
Etomidate—Hypertension—Prednisolone—hematologic cancer	0.00061	0.00173	CcSEcCtD
Etomidate—Arrhythmia—Betamethasone—hematologic cancer	0.000605	0.00172	CcSEcCtD
Etomidate—Arrhythmia—Dexamethasone—hematologic cancer	0.000605	0.00172	CcSEcCtD
Etomidate—Vomiting—Lenalidomide—hematologic cancer	0.000604	0.00171	CcSEcCtD
Etomidate—Pain—Irinotecan—hematologic cancer	0.000602	0.00171	CcSEcCtD
Etomidate—Pain—Mitoxantrone—hematologic cancer	0.000602	0.00171	CcSEcCtD
Etomidate—Bradycardia—Prednisone—hematologic cancer	0.000601	0.0017	CcSEcCtD
Etomidate—Hypotension—Cisplatin—hematologic cancer	0.000597	0.00169	CcSEcCtD
Etomidate—Vomiting—Hydroxyurea—hematologic cancer	0.000595	0.00169	CcSEcCtD
Etomidate—Pain—Gemcitabine—hematologic cancer	0.000586	0.00166	CcSEcCtD
Etomidate—Tachycardia—Etoposide—hematologic cancer	0.000571	0.00162	CcSEcCtD
Etomidate—Convulsion—Triamcinolone—hematologic cancer	0.000563	0.0016	CcSEcCtD
Etomidate—Tachycardia—Prednisolone—hematologic cancer	0.000563	0.0016	CcSEcCtD
Etomidate—Hypertension—Triamcinolone—hematologic cancer	0.000561	0.00159	CcSEcCtD
Etomidate—Vomiting—Bortezomib—hematologic cancer	0.000555	0.00158	CcSEcCtD
Etomidate—Vomiting—Bleomycin—hematologic cancer	0.000551	0.00156	CcSEcCtD
Etomidate—Hypotension—Etoposide—hematologic cancer	0.000547	0.00155	CcSEcCtD
Etomidate—Pain—Cisplatin—hematologic cancer	0.000546	0.00155	CcSEcCtD
Etomidate—Vomiting—Vinorelbine—hematologic cancer	0.000542	0.00154	CcSEcCtD
Etomidate—Arrhythmia—Prednisone—hematologic cancer	0.000527	0.0015	CcSEcCtD
Etomidate—Tachycardia—Triamcinolone—hematologic cancer	0.000518	0.00147	CcSEcCtD
Etomidate—Vomiting—Thiotepa—hematologic cancer	0.000518	0.00147	CcSEcCtD
Etomidate—Convulsion—Betamethasone—hematologic cancer	0.000511	0.00145	CcSEcCtD
Etomidate—Convulsion—Dexamethasone—hematologic cancer	0.000511	0.00145	CcSEcCtD
Etomidate—Hypertension—Betamethasone—hematologic cancer	0.000509	0.00144	CcSEcCtD
Etomidate—Hypertension—Dexamethasone—hematologic cancer	0.000509	0.00144	CcSEcCtD
Etomidate—Vomiting—Thalidomide—hematologic cancer	0.000501	0.00142	CcSEcCtD
Etomidate—Pain—Etoposide—hematologic cancer	0.0005	0.00142	CcSEcCtD
Etomidate—Pain—Prednisolone—hematologic cancer	0.000493	0.0014	CcSEcCtD
Etomidate—Vomiting—Carmustine—hematologic cancer	0.000481	0.00136	CcSEcCtD
Etomidate—Vomiting—Alitretinoin—hematologic cancer	0.000477	0.00135	CcSEcCtD
Etomidate—Pethidine—ALB—hematologic cancer	0.000471	0.088	CrCbGaD
Etomidate—Vomiting—Ifosfamide—hematologic cancer	0.000471	0.00134	CcSEcCtD
Etomidate—Tachycardia—Dexamethasone—hematologic cancer	0.00047	0.00133	CcSEcCtD
Etomidate—Tachycardia—Betamethasone—hematologic cancer	0.00047	0.00133	CcSEcCtD
Etomidate—Bradycardia—Epirubicin—hematologic cancer	0.00047	0.00133	CcSEcCtD
Etomidate—Vomiting—Vincristine—hematologic cancer	0.000459	0.0013	CcSEcCtD
Etomidate—Pain—Triamcinolone—hematologic cancer	0.000454	0.00129	CcSEcCtD
Etomidate—Hypotension—Betamethasone—hematologic cancer	0.00045	0.00128	CcSEcCtD
Etomidate—Hypotension—Dexamethasone—hematologic cancer	0.00045	0.00128	CcSEcCtD
Etomidate—Vomiting—Mitoxantrone—hematologic cancer	0.000447	0.00127	CcSEcCtD
Etomidate—Vomiting—Irinotecan—hematologic cancer	0.000447	0.00127	CcSEcCtD
Etomidate—Convulsion—Prednisone—hematologic cancer	0.000445	0.00126	CcSEcCtD
Etomidate—Hypertension—Prednisone—hematologic cancer	0.000444	0.00126	CcSEcCtD
Etomidate—Vomiting—Gemcitabine—hematologic cancer	0.000436	0.00124	CcSEcCtD
Etomidate—Bradycardia—Doxorubicin—hematologic cancer	0.000435	0.00123	CcSEcCtD
Etomidate—Arrhythmia—Epirubicin—hematologic cancer	0.000412	0.00117	CcSEcCtD
Etomidate—Pain—Betamethasone—hematologic cancer	0.000412	0.00117	CcSEcCtD
Etomidate—Pain—Dexamethasone—hematologic cancer	0.000412	0.00117	CcSEcCtD
Etomidate—Tachycardia—Prednisone—hematologic cancer	0.000409	0.00116	CcSEcCtD
Etomidate—Vomiting—Cisplatin—hematologic cancer	0.000406	0.00115	CcSEcCtD
Etomidate—Arrhythmia—Doxorubicin—hematologic cancer	0.000382	0.00108	CcSEcCtD
Etomidate—Convulsion—Methotrexate—hematologic cancer	0.000372	0.00106	CcSEcCtD
Etomidate—Vomiting—Etoposide—hematologic cancer	0.000372	0.00106	CcSEcCtD
Etomidate—Convulsion—Epirubicin—hematologic cancer	0.000348	0.000987	CcSEcCtD
Etomidate—Hypertension—Epirubicin—hematologic cancer	0.000347	0.000984	CcSEcCtD
Etomidate—Vomiting—Triamcinolone—hematologic cancer	0.000337	0.000957	CcSEcCtD
Etomidate—Hypotension—Methotrexate—hematologic cancer	0.000327	0.000929	CcSEcCtD
Etomidate—Convulsion—Doxorubicin—hematologic cancer	0.000322	0.000914	CcSEcCtD
Etomidate—Hypertension—Doxorubicin—hematologic cancer	0.000321	0.00091	CcSEcCtD
Etomidate—Tachycardia—Epirubicin—hematologic cancer	0.00032	0.000908	CcSEcCtD
Etomidate—Hypotension—Epirubicin—hematologic cancer	0.000306	0.000869	CcSEcCtD
Etomidate—Vomiting—Betamethasone—hematologic cancer	0.000306	0.000868	CcSEcCtD
Etomidate—Vomiting—Dexamethasone—hematologic cancer	0.000306	0.000868	CcSEcCtD
Etomidate—Pain—Methotrexate—hematologic cancer	0.0003	0.00085	CcSEcCtD
Etomidate—Tachycardia—Doxorubicin—hematologic cancer	0.000296	0.00084	CcSEcCtD
Etomidate—Hypotension—Doxorubicin—hematologic cancer	0.000284	0.000804	CcSEcCtD
Etomidate—Pain—Epirubicin—hematologic cancer	0.00028	0.000795	CcSEcCtD
Etomidate—Vomiting—Prednisone—hematologic cancer	0.000267	0.000756	CcSEcCtD
Etomidate—Pain—Doxorubicin—hematologic cancer	0.00026	0.000736	CcSEcCtD
Etomidate—Vomiting—Methotrexate—hematologic cancer	0.000223	0.000632	CcSEcCtD
Etomidate—Vomiting—Epirubicin—hematologic cancer	0.000209	0.000591	CcSEcCtD
Etomidate—Vomiting—Doxorubicin—hematologic cancer	0.000193	0.000547	CcSEcCtD
Etomidate—ADRA2B—GPCR downstream signaling—RASGRP1—hematologic cancer	5.02e-05	0.000128	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—FN1—hematologic cancer	5.01e-05	0.000128	CbGpPWpGaD
Etomidate—ADRA2B—GPCR ligand binding—CCL2—hematologic cancer	5e-05	0.000127	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JAK3—hematologic cancer	4.97e-05	0.000127	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ADCY7—hematologic cancer	4.92e-05	0.000126	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NCOA3—hematologic cancer	4.92e-05	0.000126	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CXCR4—hematologic cancer	4.89e-05	0.000125	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NUP214—hematologic cancer	4.89e-05	0.000125	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	4.84e-05	0.000123	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CG—hematologic cancer	4.8e-05	0.000122	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCG2—hematologic cancer	4.79e-05	0.000122	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—MTR—hematologic cancer	4.79e-05	0.000122	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCR7—hematologic cancer	4.77e-05	0.000122	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CXCL13—hematologic cancer	4.77e-05	0.000122	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL3—hematologic cancer	4.72e-05	0.00012	CbGpPWpGaD
Etomidate—GABRB2—Transmembrane transport of small molecules—ALB—hematologic cancer	4.71e-05	0.00012	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PTPN11—hematologic cancer	4.71e-05	0.00012	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NCOR2—hematologic cancer	4.71e-05	0.00012	CbGpPWpGaD
Etomidate—SLC2A1—Disease—PIK3CA—hematologic cancer	4.7e-05	0.00012	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ENO2—hematologic cancer	4.7e-05	0.00012	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CRKL—hematologic cancer	4.65e-05	0.000119	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL3RA—hematologic cancer	4.65e-05	0.000119	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.63e-05	0.000118	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.61e-05	0.000118	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—RASGRP1—hematologic cancer	4.56e-05	0.000116	CbGpPWpGaD
Etomidate—GABRA1—Transmission across Chemical Synapses—HRAS—hematologic cancer	4.56e-05	0.000116	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTT1—hematologic cancer	4.55e-05	0.000116	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—MTHFR—hematologic cancer	4.52e-05	0.000115	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—GRB2—hematologic cancer	4.52e-05	0.000115	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	4.48e-05	0.000114	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RGS2—hematologic cancer	4.48e-05	0.000114	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—SDC1—hematologic cancer	4.45e-05	0.000114	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—CREBBP—hematologic cancer	4.45e-05	0.000113	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CMA1—hematologic cancer	4.43e-05	0.000113	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TRIO—hematologic cancer	4.43e-05	0.000113	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TRH—hematologic cancer	4.43e-05	0.000113	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CG—hematologic cancer	4.41e-05	0.000113	CbGpPWpGaD
Etomidate—GABRB2—Neuronal System—HRAS—hematologic cancer	4.37e-05	0.000111	CbGpPWpGaD
Etomidate—SLC2A1—Disease—HRAS—hematologic cancer	4.35e-05	0.000111	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—PIK3CA—hematologic cancer	4.35e-05	0.000111	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AGO2—hematologic cancer	4.34e-05	0.000111	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SPHK1—hematologic cancer	4.34e-05	0.000111	CbGpPWpGaD
Etomidate—GABRG2—Transmembrane transport of small molecules—ALB—hematologic cancer	4.31e-05	0.00011	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HDAC9—hematologic cancer	4.29e-05	0.00011	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—LPAR1—hematologic cancer	4.29e-05	0.00011	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	4.25e-05	0.000108	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—H3F3B—hematologic cancer	4.25e-05	0.000108	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CD—hematologic cancer	4.22e-05	0.000108	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	4.2e-05	0.000107	CbGpPWpGaD
Etomidate—SLC2A1—Disease—IL6—hematologic cancer	4.17e-05	0.000106	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—ALB—hematologic cancer	4.16e-05	0.000106	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—GRB2—hematologic cancer	4.1e-05	0.000105	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—CREBBP—hematologic cancer	4.09e-05	0.000104	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—CSF2—hematologic cancer	4.04e-05	0.000103	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.03e-05	0.000103	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	4.01e-05	0.000102	CbGpPWpGaD
Etomidate—GABRG2—Neuronal System—HRAS—hematologic cancer	3.99e-05	0.000102	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	3.99e-05	0.000102	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3R1—hematologic cancer	3.98e-05	0.000102	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PDE4B—hematologic cancer	3.95e-05	0.000101	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CNR2—hematologic cancer	3.95e-05	0.000101	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—PIK3CA—hematologic cancer	3.94e-05	0.000101	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGF19—hematologic cancer	3.92e-05	0.0001	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—JAK1—hematologic cancer	3.9e-05	9.94e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PRKCG—hematologic cancer	3.9e-05	9.94e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RAC2—hematologic cancer	3.89e-05	9.92e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CD—hematologic cancer	3.88e-05	9.89e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—JAK2—hematologic cancer	3.87e-05	9.87e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—DKK1—hematologic cancer	3.86e-05	9.84e-05	CbGpPWpGaD
Etomidate—SLC2A1—Disease—AKT1—hematologic cancer	3.84e-05	9.81e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—ALB—hematologic cancer	3.83e-05	9.77e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT5B—hematologic cancer	3.83e-05	9.77e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CG—hematologic cancer	3.8e-05	9.7e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NQO1—hematologic cancer	3.78e-05	9.66e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CD44—hematologic cancer	3.78e-05	9.66e-05	CbGpPWpGaD
Etomidate—GABRA1—Transmembrane transport of small molecules—ALB—hematologic cancer	3.77e-05	9.62e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ADCY7—hematologic cancer	3.72e-05	9.48e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	3.71e-05	9.46e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CB—hematologic cancer	3.68e-05	9.38e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CSF2—hematologic cancer	3.67e-05	9.35e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3R1—hematologic cancer	3.66e-05	9.34e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—IL2RA—hematologic cancer	3.64e-05	9.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—XIAP—hematologic cancer	3.61e-05	9.22e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CYCS—hematologic cancer	3.58e-05	9.14e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—HSP90AA1—hematologic cancer	3.56e-05	9.08e-05	CbGpPWpGaD
Etomidate—ADRA2B—Platelet activation, signaling and aggregation—AKT1—hematologic cancer	3.55e-05	9.06e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—JAK1—hematologic cancer	3.54e-05	9.03e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PRKCG—hematologic cancer	3.54e-05	9.03e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—CREBBP—hematologic cancer	3.52e-05	8.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SH2B3—hematologic cancer	3.52e-05	8.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SMARCA4—hematologic cancer	3.52e-05	8.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GZMB—hematologic cancer	3.5e-05	8.93e-05	CbGpPWpGaD
Etomidate—GABRA1—Neuronal System—HRAS—hematologic cancer	3.49e-05	8.91e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CTNNA1—hematologic cancer	3.42e-05	8.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EIF4EBP1—hematologic cancer	3.4e-05	8.67e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HSPB1—hematologic cancer	3.4e-05	8.67e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCL3—hematologic cancer	3.4e-05	8.67e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CB—hematologic cancer	3.38e-05	8.62e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—IL2—hematologic cancer	3.38e-05	8.61e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTHLH—hematologic cancer	3.36e-05	8.57e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SDC1—hematologic cancer	3.36e-05	8.57e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CD—hematologic cancer	3.34e-05	8.53e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL2RA—hematologic cancer	3.3e-05	8.43e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—ALB—hematologic cancer	3.3e-05	8.42e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTGER4—hematologic cancer	3.27e-05	8.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—LCK—hematologic cancer	3.25e-05	8.3e-05	CbGpPWpGaD
Etomidate—SLC2A1—Metabolism—AKT1—hematologic cancer	3.22e-05	8.21e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	3.2e-05	8.17e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—H3F3A—hematologic cancer	3.19e-05	8.14e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTP1—hematologic cancer	3.16e-05	8.05e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3R1—hematologic cancer	3.16e-05	8.05e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PRKCZ—hematologic cancer	3.1e-05	7.91e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	3.05e-05	7.79e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CG—hematologic cancer	3.03e-05	7.73e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—EP300—hematologic cancer	3.03e-05	7.73e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PARP1—hematologic cancer	2.99e-05	7.64e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ABCB1—hematologic cancer	2.99e-05	7.62e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FBXW7—hematologic cancer	2.95e-05	7.52e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—SRC—hematologic cancer	2.95e-05	7.51e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PTEN—hematologic cancer	2.92e-05	7.45e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CB—hematologic cancer	2.91e-05	7.43e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—NCOR1—hematologic cancer	2.9e-05	7.4e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—GSTM1—hematologic cancer	2.9e-05	7.4e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HDAC2—hematologic cancer	2.89e-05	7.37e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CXCR4—hematologic cancer	2.89e-05	7.37e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—VEGFA—hematologic cancer	2.87e-05	7.32e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—NRAS—hematologic cancer	2.83e-05	7.23e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CBL—hematologic cancer	2.82e-05	7.19e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL3—hematologic cancer	2.79e-05	7.11e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—EP300—hematologic cancer	2.79e-05	7.11e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CG—hematologic cancer	2.75e-05	7.02e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTPN1—hematologic cancer	2.74e-05	6.99e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—MAPK3—hematologic cancer	2.71e-05	6.92e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PTPN11—hematologic cancer	2.7e-05	6.9e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—RASGRP1—hematologic cancer	2.69e-05	6.88e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HSP90AA1—hematologic cancer	2.69e-05	6.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SYK—hematologic cancer	2.69e-05	6.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CD—hematologic cancer	2.66e-05	6.8e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TGFB1—hematologic cancer	2.63e-05	6.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CREB1—hematologic cancer	2.62e-05	6.69e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT1—hematologic cancer	2.59e-05	6.61e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—MTHFR—hematologic cancer	2.56e-05	6.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—CCL2—hematologic cancer	2.56e-05	6.54e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6R—hematologic cancer	2.56e-05	6.52e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PTEN—hematologic cancer	2.52e-05	6.42e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3R1—hematologic cancer	2.52e-05	6.42e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—JAK2—hematologic cancer	2.45e-05	6.24e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—KRAS—hematologic cancer	2.44e-05	6.22e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—MAP2K1—hematologic cancer	2.44e-05	6.22e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—GRB2—hematologic cancer	2.42e-05	6.18e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CD—hematologic cancer	2.42e-05	6.17e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PDGFA—hematologic cancer	2.42e-05	6.17e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—EP300—hematologic cancer	2.4e-05	6.12e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KITLG—hematologic cancer	2.38e-05	6.08e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT5A—hematologic cancer	2.33e-05	5.94e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CB—hematologic cancer	2.32e-05	5.93e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN2B—hematologic cancer	2.31e-05	5.89e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3R1—hematologic cancer	2.28e-05	5.83e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.26e-05	5.76e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—PIK3CA—hematologic cancer	2.24e-05	5.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CD86—hematologic cancer	2.23e-05	5.7e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—JAK2—hematologic cancer	2.22e-05	5.67e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HES1—hematologic cancer	2.2e-05	5.62e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NCOR1—hematologic cancer	2.19e-05	5.59e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—TP53—hematologic cancer	2.17e-05	5.53e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGF1—hematologic cancer	2.17e-05	5.53e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CSF2—hematologic cancer	2.17e-05	5.53e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CG—hematologic cancer	2.15e-05	5.5e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FOXO1—hematologic cancer	2.13e-05	5.45e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—IL2—hematologic cancer	2.13e-05	5.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PDGFRB—hematologic cancer	2.13e-05	5.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CB—hematologic cancer	2.11e-05	5.38e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PDGFRA—hematologic cancer	2.1e-05	5.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PRKCG—hematologic cancer	2.09e-05	5.33e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JAK1—hematologic cancer	2.09e-05	5.33e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—HRAS—hematologic cancer	2.07e-05	5.29e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—PIK3CA—hematologic cancer	2.06e-05	5.26e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—CREBBP—hematologic cancer	2e-05	5.1e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL2RA—hematologic cancer	1.95e-05	4.98e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL2—hematologic cancer	1.94e-05	4.94e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TERT—hematologic cancer	1.93e-05	4.92e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CD—hematologic cancer	1.89e-05	4.83e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PDGFB—hematologic cancer	1.88e-05	4.81e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—ALB—hematologic cancer	1.87e-05	4.77e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TSC2—hematologic cancer	1.84e-05	4.7e-05	CbGpPWpGaD
Etomidate—ADRA2B—Hemostasis—AKT1—hematologic cancer	1.83e-05	4.67e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3R1—hematologic cancer	1.79e-05	4.56e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—PIK3CA—hematologic cancer	1.78e-05	4.53e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGFR3—hematologic cancer	1.77e-05	4.52e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK14—hematologic cancer	1.75e-05	4.47e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—ESR1—hematologic cancer	1.72e-05	4.39e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FN1—hematologic cancer	1.7e-05	4.34e-05	CbGpPWpGaD
Etomidate—CYP11B2—Metabolism—AKT1—hematologic cancer	1.68e-05	4.29e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—BAD—hematologic cancer	1.68e-05	4.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NFKBIA—hematologic cancer	1.68e-05	4.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NOTCH1—hematologic cancer	1.66e-05	4.24e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CB—hematologic cancer	1.65e-05	4.21e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CD80—hematologic cancer	1.63e-05	4.16e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KIT—hematologic cancer	1.63e-05	4.15e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CG—hematologic cancer	1.63e-05	4.15e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—NRAS—hematologic cancer	1.63e-05	4.15e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTPN11—hematologic cancer	1.6e-05	4.08e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—MAPK3—hematologic cancer	1.56e-05	3.97e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CREB1—hematologic cancer	1.55e-05	3.95e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—BRAF—hematologic cancer	1.53e-05	3.9e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCL2—hematologic cancer	1.51e-05	3.86e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6R—hematologic cancer	1.51e-05	3.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CREBBP—hematologic cancer	1.51e-05	3.85e-05	CbGpPWpGaD
Etomidate—CYP11B1—Metabolism—AKT1—hematologic cancer	1.45e-05	3.7e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAP2K1—hematologic cancer	1.44e-05	3.67e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CD—hematologic cancer	1.43e-05	3.65e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PTEN—hematologic cancer	1.43e-05	3.64e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—PIK3CA—hematologic cancer	1.42e-05	3.61e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—KRAS—hematologic cancer	1.4e-05	3.57e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—FGF2—hematologic cancer	1.37e-05	3.49e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—EP300—hematologic cancer	1.36e-05	3.47e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3R1—hematologic cancer	1.35e-05	3.44e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JAK2—hematologic cancer	1.31e-05	3.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—PIK3CA—hematologic cancer	1.29e-05	3.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MDM2—hematologic cancer	1.28e-05	3.27e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MTOR—hematologic cancer	1.25e-05	3.18e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CB—hematologic cancer	1.25e-05	3.18e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—HRAS—hematologic cancer	1.19e-05	3.04e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN1B—hematologic cancer	1.17e-05	2.98e-05	CbGpPWpGaD
Etomidate—ADRA2B—GPCR downstream signaling—AKT1—hematologic cancer	1.16e-05	2.95e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CASP3—hematologic cancer	1.15e-05	2.92e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL2—hematologic cancer	1.14e-05	2.92e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—IL6—hematologic cancer	1.14e-05	2.91e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CCND1—hematologic cancer	1.12e-05	2.85e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—JUN—hematologic cancer	1.11e-05	2.84e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—CDKN1A—hematologic cancer	1.08e-05	2.75e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PTEN—hematologic cancer	1.08e-05	2.75e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK8—hematologic cancer	1.05e-05	2.69e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling by GPCR—AKT1—hematologic cancer	1.05e-05	2.68e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—EP300—hematologic cancer	1.03e-05	2.62e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—PIK3CA—hematologic cancer	1.01e-05	2.57e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—SRC—hematologic cancer	9.98e-06	2.55e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—VEGFA—hematologic cancer	9.72e-06	2.48e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—STAT3—hematologic cancer	9.63e-06	2.46e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—NRAS—hematologic cancer	9.61e-06	2.45e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MAPK3—hematologic cancer	9.2e-06	2.35e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—MYC—hematologic cancer	8.95e-06	2.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TGFB1—hematologic cancer	8.93e-06	2.28e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—KRAS—hematologic cancer	8.27e-06	2.11e-05	CbGpPWpGaD
Etomidate—CYP19A1—Metabolism—AKT1—hematologic cancer	8.22e-06	2.1e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—PIK3CA—hematologic cancer	7.6e-06	1.94e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—TP53—hematologic cancer	7.35e-06	1.87e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—HRAS—hematologic cancer	7.03e-06	1.79e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—IL6—hematologic cancer	6.73e-06	1.72e-05	CbGpPWpGaD
Etomidate—ADRA2B—Signaling Pathways—AKT1—hematologic cancer	6.2e-06	1.58e-05	CbGpPWpGaD
